🇺🇸 FDA
Pipeline program

rVA576

AK580

Phase 3 small_molecule completed

Quick answer

rVA576 for Paroxysmal Nocturnal Hemoglobinuria (PNH) is a Phase 3 program (small_molecule) at Akari Therapeutics Plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Akari Therapeutics Plc
Indication
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials